麩醯胺酸 Glutamine × 腸道通透性／所謂「腸漏」(leaky gut)
結論：證據分歧
獨立判讀為 C（薄弱證據）：機轉合理（glutamine 為腸黏膜細胞主要燃料），但人體臨床端高度兩極——Achamrah 2024 meta-analysis 對腸道通透性整體效果不顯著、僅 >30 g/day 次群有改善（surrogate endpoint），單一 Zhou 2019 IBS-D RCT（n=106、單中心、效果量 79.
C 🟠 C 薄弱證據 證據分歧 🚨 high — heavy affiliate marketing in TW community
獨立判讀為 C（薄弱證據）：機轉合理（glutamine 為腸黏膜細胞主要燃料），但人體臨床端高度兩極——Achamrah 2024 meta-analysis 對腸道通透性整體效果不顯著、僅 >30 g/day 次群有改善（surrogate endpoint），單一 Zhou 2019 IBS-D RCT（n=106、單中心、效果量 79.6% vs 5.8% 異常巨大）尚未獨立複驗；同時 EFSA 已明確否決『腸黏膜完整性／正常腸道通透性』宣稱（ID 1602），Mayo/Harvard 直接質疑『leaky gut』本身的診斷正當性、AGA 未發布正式 practice update 而期刊綜述稱該詞『inappropriately labeled』。
REDOXS NEJM 2013 雖屬 ICU 外推情境，仍構成不可忽視的高劑量安全訊號（28-day mortality OR 1.28）。
整體屬『弱支持 + 概念本身未被主流醫學承認 + 重症族群明確危害』，無法達 B。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.41
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 證據分歧
信心度
72%
證據方向大致一致
證據層級
E3
單篇高品質統合分析
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.412
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
A randomized trial of glutamine and antioxidants in critically ill patients (REDOXS)
結論：INCREASED mortality signal with glutamine: 28-day mortality 32.4% vs 27.2% placebo (adjusted OR 1.28, 95% CI 1.00-1.64, p=0.05); in-hospital mortality 37.2% vs 31.0% (adjusted OR 1.34, p=0.02); 6-month mortality higher with glutamine (43.7% vs 37.2%, p=0.02). No benefit for infections or organ failure. Major counter-evidence against routine glutamine in critically ill / hemodynamically unstable populations.
前往 PubMed
Effect of glutamine supplementation on intestinal permeability: a systematic review and meta-analysis (Achamrah et al.)
結論：Overall pooled effect on intestinal permeability NOT statistically significant. Subgroup analysis suggested reduction in permeability only at doses >30 g/day; clinical relevance unclear given surrogate endpoints and small subgroup. Authors flagged high heterogeneity, mixed populations, and reliance on surrogate (lactulose/mannitol) rather than clinical outcomes.
前往 PubMed
Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome (Zhou et al.)
結論：Primary endpoint met: 79.6% of glutamine vs 5.8% of placebo achieved >=50-point IBS-SSS reduction (p<0.0001). Intestinal permeability (lactulose/mannitol ratio) significantly decreased in glutamine arm; daily bowel movements reduced. Supportive for IBS-D subset but single-center, small, no industry-independent replication.
前往 PubMed
L4a US FDA
支持
ENDARI is an amino acid indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. 來源↗
L4b EU EFSA
反對
a cause and effect relationship has not been established between the consumption of L-glutamine and growth or maintenance of muscle mass, faster restoration of muscle glycogen stores after strenuous exercise, skeletal muscle tissue repair, maintenance of normal neurological function, increased attention, improvement of working memory, and maintenance of defence against pathogenic gastro-intesti… 來源↗
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
L-麩醯胺酸 L-Glutamine：(八)營養添加劑；本品可於各類食品中視實際需要適量使用，限於補充食品中不足之營養素時使用。 來源↗
L4e WHO
中性
— 本適應症無對應資料
L5a NIH Office of Dietary Supplements
謹慎
The research to date does not support taking glutamine alone to improve exercise and athletic performance. 來源↗
L5b Mayo Clinic
反對
I don't know of any commercially-available gut test kits that will diagnose leaky gut. 來源↗
L5c Cleveland Clinic
謹慎
Vitamin D and an amino acid called L-glutamine may specifically help repair your gut lining. 來源↗
L5d Harvard Health
謹慎
Controversy still exists on whether leaky gut causes the development of diseases outside the gastrointestinal tract in humans. 來源↗
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
台灣社群多在抗癌（黏膜修復）、胃痛、功能醫學脈絡討論麩醯胺酸，少有專就「腸漏」的辯證；經驗分歧，部分回報改善，懷疑派則指人體可自行合成並引用 ICU 死亡率研究。「腸漏症」本身被視為功能醫學概念而非正式診斷，社群提醒應找腸胃發炎根因而非單靠補充。
💬社群實感
分歧（多在黏膜修復／胃腸不適脈絡有正面回饋，但專就腸漏的在地討論少、無共識）
破解迷思 社群最常見的 4 個誤解
✓
事實「腸漏症」被當成已確立疾病推銷補充品，實為功能醫學概念、非正式臨床診斷
✓
事實把麩醯胺酸當修腸漏的萬靈丹，忽略腸胃發炎多重成因與生活飲食根因
✓
事實認為一定要額外補充才夠，忽略人體可自行合成且飲食蛋白質本就含麩醯胺酸
✓
事實把抗癌／化療黏膜修復的經驗直接外推到一般人的腸漏調理
🩹 社群通報的副作用
- 高劑量恐熱量／胺基酸攝取失衡
- 肝腎功能不佳、多重器官衰竭者列為禁忌（引自 ICU 研究警示）
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- Jarrow（網購，社群推 CP 值）
- 三多 L-麩醯胺酸＋鋅
- 速養療（被嫌貴、社群多不推）
- NOW、好市多自有品牌（一般保健向）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
L10b · TFDA 法定身份 官方認定
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-gut-permeability-INT-glutamine-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "麩醯胺酸能改善腸道通透性／所謂「腸漏」(leaky gut)",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}